Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
José Manuel Baselga (1959-2021).
Scaltriti M. Scaltriti M. Science. 2021 Apr 23;372(6540):350. doi: 10.1126/science.abi7805. Science. 2021. PMID: 33888631 No abstract available.
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.
Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Lin TY, Toska E, Xu G, Kazmi A, Chang MT, Taylor BS, Dickler MN, Jhaveri K, Chandarlapaty S, Rabadan R, Reznik E, Smith ML, Sebra R, Schimmoller F, Wilson TR, Friedman LS, Cantley LC, Scaltriti M, Baselga J. Vasan N, et al. Among authors: scaltriti m. Science. 2019 Nov 8;366(6466):714-723. doi: 10.1126/science.aaw9032. Science. 2019. PMID: 31699932 Free PMC article.
José Baselga (1959-2021).
Castel P, Toska E, Vasan N, Cocco E, Scaltriti M. Castel P, et al. Among authors: scaltriti m. Cancer Cell. 2021 May 10;39(5):581-582. doi: 10.1016/j.ccell.2021.04.003. Epub 2021 Apr 29. Cancer Cell. 2021. PMID: 33930314 Free article. No abstract available.
José Baselga 1959-2021.
Scaltriti M. Scaltriti M. Nat Cancer. 2021 May;2(5):479-480. doi: 10.1038/s43018-021-00209-5. Nat Cancer. 2021. PMID: 35122018 No abstract available.
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J. Serra V, et al. Among authors: scaltriti m. Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385. Cancer Res. 2008. PMID: 18829560
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J. Eichhorn PJ, et al. Among authors: scaltriti m. Cancer Res. 2008 Nov 15;68(22):9221-30. doi: 10.1158/0008-5472.CAN-08-1740. Cancer Res. 2008. PMID: 19010894 Free PMC article.
153 results